Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Correction Notice: Inferior Outcomes of EU Versus US Patient... : HemaSphere

You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.

View original article

0 0 0 0 0 0 0

留言 (0)